We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Bristol acquires fibrotic disease company Amira for $325mm up front
29 Mar 2016
Executive Summary
Marking its first foray into the fibrotic disease area, Bristol-Myers Squibb Co. is acquiring private Amira Pharmaceuticals Inc. (developing small molecules for disorders caused by inflammation) for $325mm up front and up to $150mm in earn-outs, in three increments of $50mm each. (One of the milestone payments is expected sometime this year.)
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Acquisition
Acquisition of Private Biotech
Full Acquisition
Includes Earnout
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?